CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells

被引:30
作者
Ku, Min Jeong [1 ]
Park, Jong Woo [1 ]
Ryu, Byung Jun [1 ]
Son, Young-Jin [3 ]
Kim, Seong Hwan [2 ]
Lee, Sang Yeol [1 ]
机构
[1] Gachon Univ, Dept Life Sci, Songnam 461701, Kyeonggi Do, South Korea
[2] Korea Res Inst Chem Technol, Lab Translat Therapeut, Taejon 305600, South Korea
[3] Sunchon Natl Univ, Dept Pharm, Sunchon 540742, Jeonnam, South Korea
基金
新加坡国家研究基金会;
关键词
CK2; CX-4945; Metastasis; Matrix metalloproteinases; Human lung cancer; MATRIX METALLOPROTEINASES; KINASE CK2; EXPRESSION; APOPTOSIS; REGULATOR; CX-4945; KEY;
D O I
10.1016/j.bmcl.2013.08.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Casein kinase 2 (CK2) is known to be involved in various cellular processes such as cell cycle, apoptosis and proliferation. It has been reported that the inhibition of CK2 induced by recently developed small molecule CX4945 shows anti-cancer effects including anti-proliferation and anti-angiogenesis in several different cancers including prostate cancer. Here we report that migration and invasion of A549 human lung cancer cells are suppressed by the inhibition of CK2 induced by CX4945. We found that CX4945 sequentially attenuates the proteins in PI3K/Akt and MAPK pathways, two signaling pathways related with cell migration. This sequential control of signal pathways inhibits the expression of membrane type 1-matrix metalloproteinase and this leads to the selective attenuation of one of the gelatinases, MMP-2, which can degrade components of extracellular matrix, and metastasis of A549 human lung cancer cell. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5609 / 5613
页数:5
相关论文
共 44 条
[1]   Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1 [J].
Bae, In Hwa ;
Park, Myung-Jin ;
Yoon, Sung Hwan ;
Kang, Sung Wook ;
Lee, Seung-Sook ;
Choi, Kyung-Mi ;
Um, Hong-Duck .
CANCER RESEARCH, 2006, 66 (10) :4991-4995
[2]   Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications [J].
Basset, P ;
Okada, A ;
Chenard, MP ;
Kannan, R ;
Stoll, I ;
Anglard, P ;
Bellocq, JP ;
Rio, MC .
MATRIX BIOLOGY, 1997, 15 (8-9) :535-541
[3]  
Bierbaum S., 2012, BIOMATTER, V1, P132
[4]   The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications [J].
Carnero, Amancio ;
Blanco-Aparicio, Carmen ;
Renner, Oliver ;
Link, Wolfgang ;
Leal, Juan F. M. .
CURRENT CANCER DRUG TARGETS, 2008, 8 (03) :187-198
[5]   Uveal melanocytes produce matrix metalloproteinases-2 and-9 in vitro [J].
Chu, SC ;
Hu, DN ;
Yang, SF ;
Yang, PY ;
Hsieh, YS ;
Huang, SM ;
Yu, G ;
McCormick, SA .
PIGMENT CELL RESEARCH, 2004, 17 (06) :636-642
[6]   Kinase CK2 Inhibition: An Update [J].
Cozza, G. ;
Pinna, L. A. ;
Moro, S. .
CURRENT MEDICINAL CHEMISTRY, 2013, 20 (05) :671-693
[7]   Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers [J].
Curran, S ;
Dundas, SR ;
Buxton, J ;
Leeman, MF ;
Ramsay, R ;
Murray, GI .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8229-8234
[8]   Matrix metalloproteinases and tumor metastasis [J].
Deryugina, EI ;
Quigley, JP .
CANCER AND METASTASIS REVIEWS, 2006, 25 (01) :9-34
[9]  
Donella-Deana A., 2001, BIOCHEM J, V15, P563
[10]  
Eric B., 2003, CURR OPIN CELL BIOL, V15, P505